Recent Company News

• 09:03 AM ET Jun 23, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 05:05 PM ET Jun 23, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 07:29 PM ET Jun 27, 2025
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 10:05 AM ET Jun 23, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (89 total)

• 09:17 AM ET Jun 23, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 09:10 AM ET Jun 23, 2025
  

  Compass Pathways downgraded to in line from outperform at Evercore ISI, we're told ($4.63, 0.00)

• 08:26 AM ET Jun 23, 2025
  

  StreetAccount Summary - US Pre-market trading

• 06:33 AM ET Jun 23, 2025
  

  Compass Pathways Phase 3 trial of COMP360 psilocybin for treatment-resistant depression achieves primary endpoint ($4.63, 0.00)